Category: "Human Interest Epilepsy"

Owl and Pussycat author Edward Lear’s no-nonsense talent for capturing the moment in drawings

Owl and Pussycat author Edward Lear’s no-nonsense talent for capturing the moment in drawings

An exhibition of sketches by the English author reveals his artistic skills and life as ‘something of a sad clown’ His nonsense verse and limericks have delighted generations of readers, with The Owl and the Pussycat among English literature’s best-loved poems, but Edward Lear most wanted recognition as an oil painter of grand subjects. Now many of the […]

Soticlestat, A New Potential Treatment for Epilepsy It Inhibits Cholesterol Catabolism

Soticlestat, A New Potential Treatment for Epilepsy It Inhibits Cholesterol Catabolism

Soticlestat, a small molecule that inhibits the activity of cholesterol 24-hydroxylase, one of several enzymes responsible for catabolism of cholesterol, has the potential to translate into a useful therapy for epilepsy, but more research from clinical trials are needed, experts said. A compound that inhibits cholesterol catabolism has potential as an antiseizure drug, according to […]

Physical Activity in Epilepsy

Physical Activity in Epilepsy

Many therapists and neurologists approve physical activities as effective mediums to avoid triggers associated with epilepsy, seizures, and mental or psychological disorders. Muscle strength exercises are dedicated to reducing cognitive deterioration and suspending disease progression. Yoga, pilates, walking, jogging, and elementary aerobic exercises relate to successful epilepsy therapy programs. Some active or team sports are also acceptable to people with high […]

COLLEGE OF PHARMACY PROGRAM AWARDED $34M CONTRACT RENEWAL TO TEST AND IDENTIFY INVESTIGATIONAL THERAPEUTICS THAT PREVENT AND TREAT DRUG-RESISTANT EPILEPSY

COLLEGE OF PHARMACY PROGRAM AWARDED $34M CONTRACT RENEWAL TO TEST AND IDENTIFY INVESTIGATIONAL THERAPEUTICS THAT PREVENT AND TREAT DRUG-RESISTANT EPILEPSY

The University of Utah College of Pharmacy’s Anticonvulsant Drug Development (ADD) Program has been awarded a five-year $34 million contract renewal with the NIH’s National Institute of Neurological Disorders and Stroke (NINDS) to test and identify novel investigational therapeutics for preventing the development of epilepsy and treating refractory, or drug-resistant, epilepsy. Epilepsy is the fourth most […]

RECENT NEWS